Clinical study on piperacillin/tazobactam through different intermittent infusion in treatment of hospital-acquired pneumonia in senile patients

OBJECTIVE To compare the clinical efficacy and safety of piperacillin/tazobactam through different intermittent infusion in the treatment of senile patients with hospital acquired pneumonia.METHODS In this randomized,controlled clinical trial,the senile patients with hospital acquired pneumonia were randomly divided into 2 groups.The patients in the control group were randomized to receive piperacillin/tazobactam either by iv infusion 2.5 g for 8 hours once,and the study group was treated with 3.75 g of piperacillin/tazobactam for 12 hours once and intravenous infusion with 100 ml normal saline,the treatment course was 10-14 days in both groups.RESULTS The cure rate,total effective rate and the bacterial eradication rate were 51.43%,82.86%,and 80.00%,respectively in the study group,and were 52.78%,83.33%,and 80.56%,respectively in the control group,the incidence rates of the antibiotic-associated adverse reactions were 8.57% and 8.33%,respectively,the differences were not statistically significant;the main adverse reactions were the slight gastrointestinal upset,hepatic dysfunction,and leucopenia,which got remission after the symptomatic treatment.CONCLUSION Piperacillin/tazobactam is effective and safe in the treatment of senile patients with HAP through iv infusion 2.5g every 8h or 3.75g every 12h,the former seems more effective.